Smallpox projects send stocks soaring
The discovery of monkeypox in several countries has led to share price increases at a number of companies with smallpox vaccines or treatments in their portfolios, including Bavarian Nordic.
by marketwire, translated by catherine brett
Reports of monkeypox in several European countries have sent Bavarian Nordic’s share price soaring. On Thursday May 19, it had jumped by 30%, and by Friday lunchtime, this had increased by a further 19%.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Bavarian Nordic to supply UK with monkeypox vaccines
For subscribers
